Ariel & Lenor’s ‘Long Live Fashion Formula’ Quadruples Life of Clothes
An announcement from Procter & Gamble’s leading brands, Ariel and Lenor, today revealed its ‘Long Live Fashion Formula’ could extend the life of clothes by four times, keeping them looking new for longer. By switching from a powder to liquid or single-unit-dose format like Ariel pods, adding a Fabric Conditioner, such as Lenor, and washing on a cold and quick cycle, consumers can quadruple the life of their clothes. Extending the life of one in five garments in Europe by just 10% per year would save enough carbon to power half a million homes annually.
Global clothing production has more than doubled in the last 15 years but consumers keep clothes for just half the amount of time.1 With more than 20% discarded because they have lost their shape, colour or integrity, the fashion industry is seen to be one of the most wasteful industries in the world.
But with better fabric care, fashion can live for much longer, keeping our favourite garments out of landfills. Research by Ariel and Lenor shows the signs of aging from washing and wearing can be vastly reduced with a simple switch to the ‘Long Live Fashion Formula.’
Long Live Fashion Formula:
- Step 1 – Use a High Quality Liquid Detergent like Ariel Pods: Ariel is specifically formulated to deliver an outstanding clean, even at cooler temperatures and in quick cycles. Liquids, gels and pods are tough on stains but gentle on fabrics, keeping them clean and fresh without damaging them.
- Step 2 – Wash in Cold + Quick cycles: Washing at 40˚C uses more than double the amount of energy as washing in a Cold and Quick cycle, contributing to our individual carbon footprints. It also puts nearly double the amount of stress on your clothes with quick and cool cycles shown to extend the life of garments significantly.
- Step 3 – Add Lenor to the Drawer: Like hair conditioners keep the texture of your hair smooth, fabric conditioners keep the fibres of garments intact so they don’t lose integrity over time. This helps to protect garments from losing shape and colour, as well as stopping them from bobbling.
The research tested the stresses on garments when washing under different conditions and showed remarkable differences in garment quality for those using the long live fashion principles. Clothes require maintenance to preserve their beauty. Like hair care and skin care, keeping fabrics in good condition relies on a routine to minimise the impact of environmental factors like wear and tear.
In an Ariel/Lenor trial, 18 typical household laundry basket garments were tested, including a bodycon dress, polo shirt, printed t-shirt and denim jeans. The ‘Long Live Fashion Formula’ on average four times the lifetime of garments over 50 washes.
Quadrupling the life of just one 3kg household basket of clothing would save 230kg CO2 – the carbon equivalent of driving nearly 600 miles (870km). The life extension of just that one basket would save 7,000 litres of water needed to create new clothes – much of which would be in water scarce regions.
According to WRAP, if we extended the life of just one in five items in European wardrobes by only 10%, we could save 3 million tonnes in CO2 per year that would be generated from creating new clothes. This is equal to enough carbon to power half a million homes for a year. It could also save 150 million litres of water a year, enough to fill Big Ben 32 times over and would divert 6.4 million tonnes of clothing from landfill.
The clothes longevity initiative by Lenor is one of the first under P&G’s newly announced Ambition 2030, the company’s new sustainability goals aimed at enabling and inspiring responsible consumption among consumers - a role perfectly suited to the ‘Long Live Fashion Formula.’
Speaking about the announcement at the Copenhagen Fashion Summit, the Global VP for Fabric Enhancers at Procter & Gamble, Bert Wouters, said: “Sourcing, production and recycling are the focus of a great deal of attention in fashion, but the impact of extending the life of clothes during the so called ‘use phase’ has been largely ignored so far. We are delighted that the ‘Long Live Fashion Formula’ can help reduce the environmental burden of fashion.”
Procter & Gamble’s Research Fellow, Dr Neil Lant added: “We care for our hair and skin to keep it in good condition, so caring for your ‘second skin’ of clothes shouldn’t be any different. Clothes are subjected to stresses that age them when we wear and wash them. By using a high-quality liquid detergent that is tough on stains but gentle on fabrics and designed to work in cooler/quicker washes, and adding a fabric conditioner like Lenor, you can keep your favourite sweater looking new for much longer and reduce the environmental impact of your wardrobe.”
IMAGES AND INTERVIEW REQUESTS: To arrange interviews from the Copenhagen Fashion Summit, please contact Victoria Brophy. For photography and any other media requests, please contact the press office or go to https://rlsd.co/p/o3dwEg
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third